292 related articles for article (PubMed ID: 18220710)
1. Aldose reductase, still a compelling target for diabetic neuropathy.
Oates PJ
Curr Drug Targets; 2008 Jan; 9(1):14-36. PubMed ID: 18220710
[TBL] [Abstract][Full Text] [Related]
2. Clinical potential of aldose reductase inhibitors in diabetic neuropathy.
Hamada Y; Nakamura J
Treat Endocrinol; 2004; 3(4):245-55. PubMed ID: 16026107
[TBL] [Abstract][Full Text] [Related]
3. Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004?
Gabbay KH
Curr Diab Rep; 2004 Dec; 4(6):405-8. PubMed ID: 15539002
[TBL] [Abstract][Full Text] [Related]
4. Recent studies of aldose reductase enzyme inhibition for diabetic complications.
Suzen S; Buyukbingol E
Curr Med Chem; 2003 Aug; 10(15):1329-52. PubMed ID: 12871133
[TBL] [Abstract][Full Text] [Related]
5. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
Obrosova IG; Van Huysen C; Fathallah L; Cao XC; Greene DA; Stevens MJ
FASEB J; 2002 Jan; 16(1):123-5. PubMed ID: 11709499
[TBL] [Abstract][Full Text] [Related]
6. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats.
Ashizawa N; Yoshida M; Sugiyama Y; Akaike N; Ohbayashi S; Aotsuka T; Abe N; Fukushima K; Matsuura A
Jpn J Pharmacol; 1997 Feb; 73(2):133-44. PubMed ID: 9074947
[TBL] [Abstract][Full Text] [Related]
7. Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage.
Ho EC; Lam KS; Chen YS; Yip JC; Arvindakshan M; Yamagishi S; Yagihashi S; Oates PJ; Ellery CA; Chung SS; Chung SK
Diabetes; 2006 Jul; 55(7):1946-53. PubMed ID: 16804062
[TBL] [Abstract][Full Text] [Related]
8. Polyol pathway and diabetic peripheral neuropathy.
Oates PJ
Int Rev Neurobiol; 2002; 50():325-92. PubMed ID: 12198816
[TBL] [Abstract][Full Text] [Related]
9. [Role of polyols in the development of diabetic complications. Value of aldose-reductase inhibitors].
Brogard JM; Caro-Sampara F; Blicklé JF
Rev Med Interne; 1992; 13(1):69-79. PubMed ID: 1410879
[TBL] [Abstract][Full Text] [Related]
10. Sorbinil, an Aldose Reductase Inhibitor, in Fighting Against Diabetic Complications.
Huang Q; Liu Q; Ouyang D
Med Chem; 2019; 15(1):3-7. PubMed ID: 29792152
[TBL] [Abstract][Full Text] [Related]
11. Triglyceride-lowering effect of the aldose reductase inhibitor cemtirestat-another factor that may contribute to attenuation of symptoms of peripheral neuropathy in STZ-diabetic rats.
Prnova MS; Kovacikova L; Svik K; Bezek S; Elmazoğlu Z; Karasu C; Stefek M
Naunyn Schmiedebergs Arch Pharmacol; 2020 Apr; 393(4):651-661. PubMed ID: 31802170
[TBL] [Abstract][Full Text] [Related]
12. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor.
Yagihashi S; Yamagishi SI; Wada Ri R; Baba M; Hohman TC; Yabe-Nishimura C; Kokai Y
Brain; 2001 Dec; 124(Pt 12):2448-58. PubMed ID: 11701599
[TBL] [Abstract][Full Text] [Related]
13. Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress.
Song Z; Fu DT; Chan YS; Leung S; Chung SS; Chung SK
Mol Cell Neurosci; 2003 Aug; 23(4):638-47. PubMed ID: 12932443
[TBL] [Abstract][Full Text] [Related]
14. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
[TBL] [Abstract][Full Text] [Related]
15. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
Shindo H; Tawata M; Aida K; Onaya T
J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
[TBL] [Abstract][Full Text] [Related]
16. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
Ando H; Takamura T; Nagai Y; Kaneko S;
J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
[TBL] [Abstract][Full Text] [Related]
17. Treatment of diabetic neuropathy with inhibitors of the aldose reductase enzyme.
Green AJ; Jaspan JB
J Diabet Complications; 1990; 4(4):138-44. PubMed ID: 2151223
[No Abstract] [Full Text] [Related]
18. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
Cameron NE; Cotter MA; Basso M; Hohman TC
Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
[TBL] [Abstract][Full Text] [Related]
19. Potential use of aldose reductase inhibitors to prevent diabetic complications.
Zenon GJ; Abobo CV; Carter BL; Ball DW
Clin Pharm; 1990 Jun; 9(6):446-57. PubMed ID: 2114249
[TBL] [Abstract][Full Text] [Related]
20. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
Grewal AS; Bhardwaj S; Pandita D; Lather V; Sekhon BS
Mini Rev Med Chem; 2016; 16(2):120-62. PubMed ID: 26349493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
